Skip to content

Study · Case report or series · n = 2 · 2020

2 results

Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases.

Horowitz RI, Freeman PR, Bruzzese J

Respiratory medicine case reports21 Apr 2020Cited by 112 (Europe PMC)

PMID32322478 (opens in a new tab)PMCIDPMC7172740 (opens in a new tab)DOI10.1016/j.rmcr.2020.101063 (opens in a new tab)PepBankPUB-32322478
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In two patients with COVID-19 pneumonia, oral or intravenous glutathione improved dyspnea within 1 h.

    In plain wordsIn two patients with COVID-19 pneumonia, oral or intravenous glutathione relieved breathlessness within one hour.

    Peptide
    Glutathione
    Outcome
    DecreaseDyspnea after initial dose
    Study

    n = 2

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2 g · oral or intravenousAs given in this study (human).

    Measurements

    Time to dyspnea improvement
    ≤ 1 h
    after initial oral or intravenous glutathione use

    Source sentences

    Summary
    A trial of 2 g of PO or IV glutathione was used in both patients and improved their dyspnea within 1 h of use.
    1 context sentence
    Summary · context
    Two patients living in New York City (NYC) with a history of Lyme and tick-borne co-infections experienced a cough and dyspnea and demonstrated radiological findings consistent with novel coronavirus pneumonia (NCP).
  2. 02HumanCase report or seriesEfficacy outcome

    In two patients with COVID-19 pneumonia, repeated oral and intravenous glutathione further relieved respiratory symptoms.

    In plain wordsIn two patients with COVID-19 pneumonia, repeated oral and intravenous glutathione further relieved respiratory symptoms.

    Peptide
    Glutathione
    Outcome
    DecreaseRespiratory symptoms after repeated doses
    Study

    n = 2

    Outcome group
    Respiratory function · Respiratory
    Studied dose
    2000 mg · oral or intravenousAs given in this study (human).

    Source sentences

    Summary
    Repeated use of both 2000 mg of PO and IV glutathione was effective in further relieving respiratory symptoms.
    1 context sentence
    Summary · context
    Two patients living in New York City (NYC) with a history of Lyme and tick-borne co-infections experienced a cough and dyspnea and demonstrated radiological findings consistent with novel coronavirus pneumonia (NCP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.